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Conclusions For the first time, we demonstrated that the 
renal function of some patients, which had deteriorated 
following zoledronic acid administration, successfully 
improved after changing to denosumab.
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BMA  Bone-modifying agent
Ccr  Creatinine clearance ratio
IQR  Interquartile range
PC  Prostate cancer
PS  Performance status
RCC  Renal cell cancer
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Introduction
Bone is a major metastatic site for urologic malignan-
cies as well as many solid tumors. Indeed, prostate cancer 
(PC) has a very high proclivity for metastasizing to bone, 
with ~90 % of men with advanced disease having skeletal 
lesions [1]. In terms of urothelial cancer (UC), bone is also 
the most common visceral metastatic site from bladder UC, 
accounting for nearly half of the patients with metastatic 
UC [2]. In addition, bone is also a common metastatic site 
in patients with metastatic renal cell cancer (RCC), being 
second only to the lung, with estimates of frequency rang-
ing from 24−51 % [3]. Bone metastases often create seri-
ous clinical problems—they lead to poor performance sta-
tus due to pathologic fractures, spinal cord compression, 
and intractable pain, commonly referred to as skeletal-
related events (SREs) [4–9]. Therefore, the diagnosis and 
Abstract  
Background In order to help in selecting the optimum 
bone-modifying agent (BMA; zoledronic acid or deno-
sumab), we investigated the impact of the BMA on the 
renal function of patients with bone metastases.
Materials and methods The present study consisted of 118 
patients who were treated with denosumab for bone metas-
tases secondary to prostate cancer, renal cell cancer, and 
urothelial cancer at our hospital between 2012 and 2015. 
The clinical course of the renal function of these patients, 
treated with zoledronic acid or denosumab, was retrospec-
tively evaluated.
Results Of the 118 patients who were treated with deno-
sumab during the study period, 57 (48 %) had previ-
ously been administered zoledronic acid and 61 (52 %) 
had received denosumab as the first-line BMA. The rea-
sons for changing from zoledronic acid to denosumab 
were increased creatinine serum level (26 patients, 46 %), 
patient preference (16 patients, 28 %), difficulty with 
venous infusion (10 patients, 17 %), and other reasons (5 
patients, 9 %). The median level of creatinine clearance 
in the patients who changed from zoledronic acid to den-
osumab due to increased serum creatinine level was 59.9 
ml/min before administration of zoledronic acid, 40.9 ml/
min at the beginning of denosumab treatment, 47.5 ml/
min at 3 months after administration of denosumab, and 
52.0 ml/min at the last follow-up. There were significant 
differences.
 * Takeshi Yuasa 
 takeshi.yuasa@jfcr.or.jp
1 Department of Urology, Cancer Institute Hospital, Japanese 
Foundation for Cancer Research, Ariake, Tokyo 135-8550, 
Japan
1192 Int J Clin Oncol (2016) 21:1191–1195
1 3
management of bone metastasis play important roles in the 
medical treatment of urological malignancies.
In order to prevent SREs associated with bone metasta-
ses, the use of bone-modifying agents (BMAs) is currently 
widespread in urological clinical practice [7–9]. The third-
generation bisphosphonate, zoledronic acid (Zometa®; 
Novartis Pharma AG, Basel, Switzerland), an inhibitor of 
bone resorption, is the first authorized BMA, and is one 
of the standards of care for SREs resulting from meta-
static bone lesions in various cancers [4–7]. Denosumab 
(XGEVA®; Amgen, Thousand Oaks, CA, USA) is another 
BMA that received approval for clinical use in April 2012 
in Japan [8–11]. Denosumab is a fully human monoclo-
nal antibody that binds to and neutralizes the receptor 
activator of nuclear factor-kappa B ligand (RANKL; also 
called tumor necrosis factor ligand superfamily member 
11; TNFSF11), thereby inhibiting osteoclast function and 
preventing generalized bone resorption and local bone 
destruction [8–11]. In phase III clinical trials, denosumab 
was demonstrated to be non-inferior (trending to superior) 
to zoledronic acid in preventing or delaying first on-study 
SREs in patients with various malignant tumors, including 
urological cancers [8–11]. Selecting the optimum BMA, 
zoledronic acid or denosumab, however, remains unspeci-
fied. Renal dysfunction is considered to be one of the main 
reasons for dose reduction in zoledronic acid therapy [8–
11]. In this study, we report the improvement of renal func-
tion by changing the BMA from zoledronic acid to deno-
sumab in patients with urological malignancies.
Materials and methods
Patients and treatment
The medical records of patients who were treated with den-
osumab for bone metastases secondary from prostate can-
cer (PC), renal cell cancer (RCC), and UC at our institute 
between 2012 and 2015 were retrospectively reviewed. In 
order to prevent an effect caused by the deterioration of the 
primary disease, we included patients treated with deno-
sumab for at least 3 months and excluded patients treated 
with denosumab for <3 months. In all patients, bone metas-
tasis was confirmed by bone scans and computed tomog-
raphy and/or magnetic resonance imaging. We considered 
clinical factors, common laboratory blood and serum data, 
presence or absence of prior zoledronic acid treatment, rea-
son for the change to denosumab, and the clinical course of 
renal function. The creatinine clearance ratio (Ccr) was cal-
culated according to the method of Cockcroft: {[140 − age 
(years)] × weight (kg)}/[72 × serum creatinine (mg/dl)] 
(multiplied by 0.85 for women and by 1 for men)}. As for 
zoledronic acid, dose adjustment as per Ccr is necessary. 
According to the manufacturer’s protocol, 4 mg of zole-
dronic acid (full dose) can be administered when Ccr is 
≥60; however, when Ccr is 60 > Ccr ≥ 50, 50 > Ccr ≥ 40, 
and 40 > Ccr ≥ 30, a reduced dose of 3.5, 3.3, and 3.0 mg 
of zoledronic acid, respectively, should be administered in 
clinical practice [12]. This study was carried out in com-
pliance with the Declaration of Helsinki and was approved 
by the institutional review board at the Cancer Institute 
Hospital.
Statistical analysis
The duration of follow-up was calculated from the date of 
initial administration of BMA to the last administration 
or the last follow-up. The difference in renal function was 
compared using Student’s t test. Factors associated with 
changes in renal function were extracted by logistic regres-
sion analysis. Statistical analyses were performed using 
the Statistical Package for Social Sciences, version 17.0 
for Windows (SPSS Inc., Chicago, IL, USA). Two-tailed 
p < 0.05 was considered significant.
Results
Characteristics of patients treated with denosumab
In the medical records of our institute, we found 118 
patients who had been treated with denosumab during the 
study period. The characteristics of these patients are shown 
in Table 1. The median age of these patients was 71.5 years 
Table 1  Characteristics of 
patients with bone metastasis 
who were treated with bone-
modifying agents
a Numbers represent median (IQR)
Variables
Age (years) 71.5 (64.9–76.7)a
Male/female (cases) 101/17
Disease (cases) renal cell cancer/urothelial cancer/prostate cancer 22/27/69
First-line bone-modifying agent (case)
 Zoledronic acid 57
 Denosumab 61
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(intraquartile range [IQR] 64.9–76.7 years). The median 
follow-up period from administration of denosumab to the 
last follow-up date was 7.6 months (IQR 4.2–13.2 months). 
Among these patients, 69 (58 %), 27 (23 %), and 22 (19 %) 
had PC, RCC, and UC, respectively. Of the 118 patients, 
101 (86 %) were male, and 17 (14 %) were female. Zole-
dronic acid had previously been administered to 57 patients 
(48 %) and 61 (52 %) had received denosumab as the first-
line BMA. The median number of zoledronic acid admin-
istrations was 15 (IQR 8–27 times) and the median dose of 
the last administration of zoledronic acid was 3.3 mg/body 
(IQR 3.0–4.0).
Renal function of patients treated with denosumab 
as the first‑line BMA
In the 61 patients who received denosumab as the first-
line BMA, the median follow-up period from the admin-
istration of denosumab to the last follow-up date was 
7.7 months (IQR 4.2–13.3 months). Among these patients, 
32 (52 %), 11 (18 %), and 18 (30 %) had PC, RCC, and 
UC, respectively. The median level of Ccr before, at 
3 months after administration of denosumab, and at the 
last follow-up was 74.6 ml/min (IQR 51.2–93.2 ml/min), 
78.8 ml/min (IQR 57.4–94.3 ml/min), and 73.3 ml/min 
(IQR 59.2–98.8 ml/min), respectively. There was no sta-
tistically significant difference among these renal function 
levels.
Renal function of patients previously treated 
with zoledronic acid
Among the 57 patients who received denosumab as the 
second-line BMA following zoledronic acid, the median 
follow-up period from administration of zoledronic 
acid to the last follow-up date was 6.7 months (IQR 
3.7–13.3 months). Among these patients, 37 (65 %), 16 
(28 %), and 4 (7 %) had PC, RCC, and UC, respectively. 
The median number of zoledronic acid administrations 
was 15 (IQR 8–27 times) and the reasons for chang-
ing were increased creatinine serum level (26 patients, 
46 %), patient preference (16 patients, 28 %), difficulty 
with venous infusion (10 patients, 17 %), and other rea-
sons (5 patients, 9 %). We compared the clinical varia-
bles between the patients who changed from zoledronic 
acid to denosumab due to increased serum level (n = 26) 
and the residual patients (n = 31) (Table 2). The median 
Ccr levels at the initial denosumab administration were 
75.4 and 40.9 ml/min, respectively, showing a statisti-
cal difference. We found that older age and lower Ccr 
level were potential risk factors for renal function dete-
rioration during zoledronic acid therapy. In addition, the 
median level of Ccr before and after administration of 
zoledronic acid was 68.0 ml/min (IQR 51.1–91.1 ml/min) 
and 59.5 ml/min (IQR 39.7–76.4 ml/min), respectively 
(Fig. 1a). The median levels of Ccr before, at 3 months 
after administration of denosumab, and at the last follow-
up were 59.5 ml/min (IQR 39.7–76.4 ml/min), 63.3 (IQR 
46.3–92.6 ml/min), and 64.4 ml/min (IQR 48.3–90.5 ml/
min), respectively (Fig. 1a). Although the Ccr tended to 
decrease with zoledronic acid treatment and recover with 
denosumab treatment, there was no statistically signifi-
cant difference. 
Renal function of patients changing from zoledronic 
acid to denosumab because of renal function 
deterioration
Among 26 patients who changed due to renal function 
deterioration, 14 (54 %), 9 (35 %), and 3 (11 %) had PC, 
RCC, and UC, respectively. The median number of zole-
dronic acid treatments was 17.5 (IQR 15–27.5) and the 
median number of denosumab treatments was 9.5 (IQR 
5.25–13.75). The median level of Ccr before and after 
administration of zoledronic acid was 59.9 ml/min (IQR 
46.9–73.9 ml/min) and 40.9 ml/min (IQR 33.3–55.0 ml/
min), respectively (Fig. 1b), showing a statistically signifi-
cant difference (p < 0.001).
Table 2  Comparison of clinical variables between patients who showed deterioration of renal function during zoldronic acid therapy and 
patients who changed to denosumab due to other causes
a Numbers represent median (inter-quartile range)
Variables Deteriorated renal function Other causes Probability
Creatinine clearance rate at denosumab induction (ml/min) 40.9 (33.3–55.0) 75.4 (61.4–103.0)a <0.0001
Age (years) 74.6 (71.4–79.2)a 68.3 (64.1–75.1)a 0.007
Male/female (cases) 23/3 27/4 0.772
Disease (cases) renal cell cancer/urothelial cancer/prostate cancer 9/3/14 7/1/23 0.336
Creatinine clearance rate at zoledonic acid induction (ml/min) 59.5 (45.3–73.5)a 78.2 (58.3–93.3)a 0.016
Number of zoledronic acid administrations 17.5 (15–27.5)a 14 (6.3–32.3)a 0.980
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The median levels of Ccr at the beginning of deno-
sumab treatment, 3 months after the administration of 
denosumab, and at the last follow-up were 40.9 ml/min 
(IQR 33.3–55.0 ml/min), 47.5 ml/min (IQR 36.5–61.7 ml/
min), and 52.0 ml/min (IQR 41.5–62.8 ml/min), respec-
tively (Fig. 1b). The Ccr significantly recovered 3 months 
after denosumab treatment and at last follow-up (p < 0.001, 
p < 0.001, respectively). In addition, the median increased 
Ccr during denosumab therapy was 10.0 ml/min (IQR 
3.0–15.8 ml/min). When we divided these patients into two 
groups according to changes in Ccr, the Ccr levels at last 
follow-up of the patients whose Ccr improved by >10 ml/
min and of the residual patients (<10 ml/min) were 58.0 
(IQR 48.4–74.8 ml/min) and 45.0 (IQR 36.0–50.3 ml/min), 
respectively, showing a statistical difference (p = 0.012). 
We then compared the clinical variables between these two 
groups including age, gender, disease, administration times 
of zoledronic acid, Ccr at initial zoledronic acid adminis-
tration, and Ccr at initial denosumab administration; how-
ever, there was no statistical difference between the groups.
Discussion
For patients with bone metastasis, zoledronic acid or deno-
sumab is administered as a BMA to prevent SREs. To date, 
two classes of pharmaceutic agents, zoledronic acid and 
denosumab, have received approval by regulatory agencies 
for use in the treatment of patients with bone metastasis. 
Denosumab has several beneficial points compared with 
zoledronic acid, namely, the convenience of subcutaneous 
administration and the fact that strict renal function moni-
toring and dose adjustment are not needed. Indeed, during 
this study period, 57 patients switched from zoledronic acid 
to denosumab. Increased creatinine serum level (26 patients 
46 %), patient preference (16 patients 28 %), and difficulty 
with venous infusion (10 patients 17 %) were the main rea-
sons for the change.
Renal toxicity caused by zoledronic acid is a well-known 
adverse event. Post-marketing surveillance has revealed 
a number of cases of renal failure with zoledronic acid [13, 
14]. In 2003, the United States Food and Drug Administration 
(FDA) reported 72 cases of renal failure associated with zole-
dronic acid, including 27 patients who required dialysis [13]. 
Consequently, zoledronic acid requires a dose adjustment for 
a Ccr of 30–60 ml/min, as described in the ‘Materials and 
methods’ section. In this study, due to deteriorated renal func-
tion, 26 of 57 (46 %) patients changed from zoledronic acid to 
denosumab. This renal toxicity leads to reduced relative dose 
intensity and might reduce the drug’s efficacy as a BMA.
Three large international double-blind studies compared 
denosumab with zoledronic acid for the treatment of bone 
metastases in patients with castration-resistant prostate 
cancer (n = 1,904), breast cancer (n = 2,046), and other 
advanced cancers or multiple myelomas (n = 1,776) [8–10]. 
The superior results of denosumab in these clinical trials 
were considered to arise from the difference in relative dose 
intensity. Among the patients treated with zoledronic acid 
in these three studies, 502 (18 %) had dose adjustments at 
baseline due to impaired Ccr. In addition, during the study, 
277 (10 %) patients had doses withheld due to a decrease in 
Ccr. Moreover, among these 277 patients, 143 (52 %) had 
PC [14]. In urological malignancies, including RCC and UC 
of the upper urinary tract, many patients have only one kid-
ney due to prior nephrectomy. As such, urologists must pay 
careful attention to renal function when treating urologi-
cal malignancies. In this study, we were unable to compare 
the efficacy between the zoledronic acid and denosumab. 
However, we demonstrated that the renal function of some 
patients treated with zoledronic acid deteriorated during the 
study period. Older age and lower Ccr might be potential 
risk factors during zoledronic acid therapy.
In contrast, in terms of administration of denosumab 
for patients with impaired renal function, the renal func-
tion did not have a significant effect on denosumab 
Fig. 1  Changes in the creatinine clearance ratio in patients treated by 
zoledronic acid followed by denosumab therapy. Renal function of 
all patients who changed from zoledronic acid to denosumab for any 
cause (a). Renal function of patients who changed from zoledronic 
acid to denosumab due to deterioration of renal function (b). ZOL 
zoledronic acid, DEN denosumab, *statistically significant difference 
between values (p < 0.001)
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pharmacokinetics or pharmacodynamics [15]. In this 
study, we discontinued zoledronic acid for renal function-
impaired patients and commenced denosumab therapy 
immediately. None of the 27 patients who had deteriorated 
renal function and then started denosumab treatment exhib-
ited a decreased Ccr during denosumab therapy. There-
fore, we can recommend initiation of denosumab treatment 
and suspension of zoledronic acid when patients exhibit 
impaired renal function during zoledronic acid treatment. 
Our data also demonstrated some cases in which renal 
function was improved by changing from zoledronic acid 
to denosumab.
The major limitations of our study were the retrospec-
tive design and the small size of the study cohort. In addi-
tion, we cannot compare the efficacy between zoledronic 
acid and denosumab in terms of preventing SREs. To 
date, no report has clearly recommended that changing to 
denosumab can be a useful choice. We believe that these 
results reflect the treatment characteristics in patients with 
bone metastases in current clinical practice in urological 
malignancies.
In conclusion, we demonstrated for the first time that 
the renal function of some patients, which had deteriorated 
following zoledronic acid administration, successfully 
improved after changing to denosumab. Zoledronic acid-
caused renal function deterioration is one of the main rea-
sons for the relative dose intensity reduction as a BMA. We 
recommend that denosumab be used in patients who expe-
rience reduced renal function following zoledronic acid 
administration.
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